Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2011-01-11
2011-01-11
Jones, D L (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001490, C424S009200, C435S005000
Reexamination Certificate
active
07867476
ABSTRACT:
The invention consists of assay methods, assay kits and antibodies for detecting the polypeptide fragments of dystrophin protein cleavage by enteroviral protease 2A as a result of an enteroviral infection in the heart. The presence of dystrophin cleavage products in the myocytes or blood of a subject is diagnostic for enteroviral infection and myocarditis resulting therefrom.
REFERENCES:
patent: 5308752 (1994-05-01), Campbell et al.
patent: 5418139 (1995-05-01), Campbell
patent: 5571698 (1996-11-01), Ladner et al.
patent: 6057098 (2000-05-01), Buechler et al.
patent: 3939200 (1991-05-01), None
patent: 19846271 (2000-04-01), None
patent: 2851046 (2004-08-01), None
patent: WO 89/09790 (1989-10-01), None
Badorff et al, Nature Medicine, Mar. 1999, vol. 5, No. 3, pp. 320-326.
Cabily, et al. “Generation of Antibody Activity from Immunoglobulin Polypeptide Chains Produced inEscherichia coli”, Proc. Natl. Acad. Sci.USA, 81:3273, 1984.
Cwirla et al., “Peptides on Phage: A vast library of peptides for identifying ligands”, Proc. Natl. Acad. Sci. USA 87, 6378-82, 1990.
Devlin et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules”, Science 249, 404-6, 1990.
Feldman and McNamara, “Myocarditis”,New Engl.J.Med., 343:1388-1398, at 1393 (2000).
Fujiwara et al., “Synthesis of Human C-Type Natriuretic Peptide 22 Using Chlorotrityl Resin and Tetrafluoroboric Acid Deprotection”, Chem. Pharm. Bull. (Tokyo) 44: 1326-31, 1996.
Huse, et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”,Science, 246:1275-1281, 1989.
Huse et al., “Application of a Filamentous Phage pVIII Fusion Protein system Suitable for Efficient Production, Screening, and Mutagenesis of F(ab) Antibody Fragments”, J. Immunol. 149, 3914-3920 (1992.
Ishiwata, et al., “Studies of 18F-labeled pyrimidines”,Eur.J.Nucl.Med., 9:185-189, 1984.
Keough, et al, “An Improved Method For Synthesis and Purification of 125I or 131I labeled Carrier-Free 5-IODO-1′-Deoxyuridine”,J.Labeled Compound Radiopharm., 14:83-90, 1978.
Kiso et al., “Solution-Phase Synthesis of Porcine Brain Natriuretic Peptide (pBNP) Using S-Trimethylacetamido-methylcystein”, Chem. Pharm. Bull. (Tokyo) 38: 1192-99, 1990.
Kubota, et al., “Differential Diagnosis of AH109A Tumor and Inflammation by Radioscintigraphy with L-[Methyl-11C] methionine”,Jpn.J.Cancer Res., 80:778-782, 1989.
Makrigiorgos, et al., “Inhomogeneous Deposition of Radiopharmaceuticals at the Cellular Level: Experimental Evidence and Dosimetric Implications”,J.Nucl.Med., 31:1358-1363, 1990.
Mostafavi et al,Synthesis, Purification and Biological Activity of (SER10-Phosphatidyl)-Urodilatin (Phosphourodilatin), Biomed. Pept. Proteins Nucleic Acids 1: 255-60, 1995.
Mullinax, et al., “Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage λ immunoexpression library”,Proc. Natl. Acad. Sci., 87:8095-8099, 1990.
Riechmann, et al., “Reshaping Human Antibodies for Therapy”,Nature332:323, 1988.
Scott and Smith, “Searching for Peptide Ligands with an Epitope Library”, Science 249, 386-88, 1990.
Shaw, et al.,“Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen”,J. Immun., 138:4534 (1987.
Sheng, et al.,“Cardiotrophin 1 (CT-1) Inhibition of Cardiac Myocyte Apoptosis Via A Mitogen=activated Protein Kinase-dependent Pathway”,J.Biol.Chem., 272:5783-5791 (1997.
Spira, et al., “The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay”,J. Immunol. Methods, 74:307, 1984.
Sun, L.K., et al., “Chimeric Antibody With Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A”,Proc. Natl. Acad. Sci.USA, 84:214-218 (1987).
Steplewski, et al.,“Isolation and Characterization of Anti-monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants”,Proc. Natl. Acad. Sci.U.S.A., 82:8653, 1985.
Ward et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted fromEscherichia coli”, (1989)Nature341:544-546).
Wilson et al., “Simplified Conjugation Chemistry for Coupling Peptides to F(ab′) Fragments: Autologous Red Cell Agglutination Assay for HIV-1 Antibodies”, (1994) J. Immunol. Methods 175:267-273.
Yarmush M.L, et al., “Coupling of Antibody-Binding Fragments to Solid-Phase Supports: Site-Directed Binding of F(ab′)2 Fragments”, (1992) J. Biochem. Biophys. Methods 25:85-97.
Miyatake et al, “Dystrophin: localization and presumed function,” Muscle & Nerve, 14(2): 113-119 (1991).
Chevron et al, “Expression and subcellular localization of dystrophin in skeletal, cardiac and smooth muscles during the human development,” Neurmuscular Disorders, 4( 5-6):419-432 (1994).
Lee et al, “Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy,” Circulation Research, 87(6): 489-495 (2000).
Supplemental European Search Report from Corresponding European Patent Application No. 05741824.
Knowlton Kirk
Tsimikas Sotirios
DLA Piper (LLP) US
Jones D L
The Regents of the University of California
LandOfFree
Method and materials for use in diagnosing viral myocarditis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and materials for use in diagnosing viral myocarditis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and materials for use in diagnosing viral myocarditis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678678